AGBL2 and rheumatoid arthritis: Besides the difference in reactivity between RA patients (especially the anti-CCP2-positive patients) and the healthy controls, a difference also was found in the size of signals against the individual peptide backbones that was common to both citrullinated peptides and to arginine-containing control peptides, as well as to both RA patients and controls.